A study of injectable formulation of DUR-928 in patients with moderate and severe acute liver function impairment.
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs DUR 928 (Primary)
- Indications Liver disorders
- Focus Adverse reactions; Pharmacokinetics
- 08 Nov 2017 New trial record